Objective: The 18F-labeled Deoxy-D-Glucose exhibits high affinity to cancer tissue as a PET (Positron Emission Tomography) imaging agent for metastatic cancers. Complexation of 10B to 18F-DG complex may create a useful BNCT (Boron Neutron Capture Therapy) agent for cancer therapy. In previous studies, complexation and characterization of 10B with DG were evaluated and biodistribution analysis was completed successfully. Radioactive tracer labeled 10B-DG will be a useful approach to uses for BNCT applications. Methods: The 18F-DG synthesized by ion exchange and complexed with 10B(OH)3 via pH reactions. 18F-DG-10B complexation was assayed with Agilent 1260 Infinity HPLC-DAD and Agilent 6420 Triple Quad LC/MS. Complexed molecule defragmented and fragmentation products assayed with Agilent 6420 Triple Quad LC/MS for confirmation. Results: 10B-18F-DG complex was obtained with ion-exchange pH reaction successfully. Complexation of two 10B(OH)3 to 18F-DG was determined with Triple Quad LC/MS. Purification of 10B-18F-DG is currently in progress. Conclusions: Radio-labelled 10B-DG will supply new insight to research for BNCT studies. Cancer detection and therapy will be applicable in the same schedule with 10B-18F-DG complex. |
Boron Neutron Capture Therapy Borono 2-Deoxy-D-glucose Boronophenylalanine Glucose 2-Fluoro-2-deoxy-D-glucose
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Research Article |
Authors | |
Publication Date | July 31, 2017 |
Published in Issue | Year 2017 Volume: 4 Issue: 7 |